Collection 5 (Sep 2024 - Aug 2025) Articles

Articles
Early Ezetimibe Initiation After Myocardial Infarction Protects Against Later Cardiovascular Outcomes in the SWEDEHEART Registry
Leosdottir M, Schubert J, Brandts J, et al.
Journal:
J Am Coll Cardiol

First published: April 22, 2025 DOI: 10.1016/j.jacc.2025.02.007
View
- Share
Articles
Intensive Lowering of LDL Cholesterol Levels With Evolocumab in Autoimmune or Inflammatory Diseases: An Analysis of the FOURIER Trial
Zimerman A, Kunzler ALF, Weber BN, et al.
Journal:
Circulation

First published: April 21, 2025 DOI: 10.1161/CIRCULATIONAHA.124.072756
View
- Share
Articles
LDL-cholesterol levels and lipid lowering therapy in secondary prevention. Baseline data from the BRING-UP prospective registry
Colivicchi F, Fabbri G, Oliva F, et al.
Journal:
Int J Cardiol

First published: April 19, 2025 DOI: 10.1016/j.ijcard.2025.133290
View
- Share
Articles
Efficacy and safety of inclisiran based on background lipid-lowering treatment
Landmesser U, Koenig W, Leiter LA, et al.
Journal:
Eur J Prev Cardiol

First published: April 17, 2025 DOI: 10.1093/eurjpc/zwaf214
View
- Share
Articles
Apolipoprotein C3 and cardiovascular risk: New insights from the ODYSSEY Outcomes trial
Catapano AL, Pirillo A, Tokgözoğlu L
Journal:
Eur J Prev Cardiol

First published: April 15, 2025 DOI: 10.1093/eurjpc/zwaf202
View
- Share
Articles
Implementation strategies for improving the care of familial hypercholesterolaemia from the International Atherosclerosis Society: next steps in implementation science and practice
Sarkies MN, Watts GF, Gidding SS, et al.
Journal:
Am J Prev Cardiol

First published: April 14, 2025 DOI: 10.1016/j.ajpc.2025.100993
View
- Share
Articles
Relation of Low-Density Lipoprotein Cholesterol, High-Sensitivity C-Reactive Protein, and Lipoprotein(a) Each to Future Cardiovascular Events and Death After Acute Coronary Syndrome on High-Intensity Statin Therapy: An Analysis of the Placebo Arm of ODYSSEY OUTCOMES
Steg PG, Szarek M, Jukema JW, et al.
Journal:
Circulation

First published: April 7, 2025 DOI: 10.1161/CIRCULATIONAHA.124.071269
View
- Share
Articles
Effects of Evolocumab on Coronary Plaque Composition and Microcalcification Activity by Coronary PET and CT Angiography
Han D, Tzolos E, Park R, et al.
Journal:
JACC Cardiovasc Imaging

First published: April 2, 2025 DOI: 10.1016/j.jcmg.2025.01.005
View
- Share
Articles
Low-density lipoprotein cholesterol, C-reactive protein, and lipoprotein(a) universal one-time screening in primary prevention: the EPIC-Norfolk study
Kraaijenhof JM, Nurmohamed NS, Nordestgaard AT, et al.
Journal:
Eur Heart J

First published: April 1, 2025 DOI: 10.1093/eurheartj/ehaf209
View
- Share
Articles
An Oral PCSK9 Inhibitor for Treatment of Hypercholesterolemia: The PURSUIT Randomized Trial
Koren MJ, Vega RB, Agrawal N, et al.
Journal:
J Am Coll Cardiol

First published: March 31, 2025 DOI: 10.1016/j.jacc.2025.03.499
View
- Share
Articles
Durability and efficacy of solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3, in adults with mixed dyslipidaemia (PROLONG-ANG3): a double-blind, randomised, placebo-controlled, phase 2 trial
Ray KK, Oru E, Rosenson RS, et al.
Journal:
Lancet

First published: March 31, 2025 DOI: 10.1016/S0140-6736(25)00507-0
View
- Share
Articles
Effect of ANGPTL3 Inhibition With Solbinsiran in Preclinical and Early Human Studies
Ray KK, Linnebjerg H, Michael LF, et al.
Journal:
J Am Coll Cardiol

First published: March 30, 2025 DOI: 10.1016/j.jacc.2025.03.005
View
- Share

1 … 3 4 5 6 7 … 10

Collection 5 (Sep 2024 - Aug 2025) Articles

Articles

Early Ezetimibe Initiation After Myocardial Infarction Protects Against Later Cardiovascular Outcomes in the SWEDEHEART Registry

Leosdottir M, Schubert J, Brandts J, et al.

Articles

Intensive Lowering of LDL Cholesterol Levels With Evolocumab in Autoimmune or Inflammatory Diseases: An Analysis of the FOURIER Trial

Zimerman A, Kunzler ALF, Weber BN, et al.

Articles

LDL-cholesterol levels and lipid lowering therapy in secondary prevention. Baseline data from the BRING-UP prospective registry

Colivicchi F, Fabbri G, Oliva F, et al.

Articles

Efficacy and safety of inclisiran based on background lipid-lowering treatment

Landmesser U, Koenig W, Leiter LA, et al.

Articles

Apolipoprotein C3 and cardiovascular risk: New insights from the ODYSSEY Outcomes trial

Catapano AL, Pirillo A, Tokgözoğlu L

Articles

Implementation strategies for improving the care of familial hypercholesterolaemia from the International Atherosclerosis Society: next steps in implementation science and practice

Sarkies MN, Watts GF, Gidding SS, et al.

Articles

Relation of Low-Density Lipoprotein Cholesterol, High-Sensitivity C-Reactive Protein, and Lipoprotein(a) Each to Future Cardiovascular Events and Death After Acute Coronary Syndrome on High-Intensity Statin Therapy: An Analysis of the Placebo Arm of ODYSSEY OUTCOMES

Steg PG, Szarek M, Jukema JW, et al.

Articles

Effects of Evolocumab on Coronary Plaque Composition and Microcalcification Activity by Coronary PET and CT Angiography

Han D, Tzolos E, Park R, et al.

Articles

Low-density lipoprotein cholesterol, C-reactive protein, and lipoprotein(a) universal one-time screening in primary prevention: the EPIC-Norfolk study

Kraaijenhof JM, Nurmohamed NS, Nordestgaard AT, et al.

Articles

An Oral PCSK9 Inhibitor for Treatment of Hypercholesterolemia: The PURSUIT Randomized Trial

Koren MJ, Vega RB, Agrawal N, et al.

Articles

Durability and efficacy of solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3, in adults with mixed dyslipidaemia (PROLONG-ANG3): a double-blind, randomised, placebo-controlled, phase 2 trial

Ray KK, Oru E, Rosenson RS, et al.

Articles

Effect of ANGPTL3 Inhibition With Solbinsiran in Preclinical and Early Human Studies

Ray KK, Linnebjerg H, Michael LF, et al.

Articles

Early Ezetimibe Initiation After Myocardial Infarction Protects Against Later Cardiovascular Outcomes in the SWEDEHEART Registry

Leosdottir M, Schubert J, Brandts J, et al.

Share

Articles

Intensive Lowering of LDL Cholesterol Levels With Evolocumab in Autoimmune or Inflammatory Diseases: An Analysis of the FOURIER Trial

Zimerman A, Kunzler ALF, Weber BN, et al.

Share

Articles

LDL-cholesterol levels and lipid lowering therapy in secondary prevention. Baseline data from the BRING-UP prospective registry

Colivicchi F, Fabbri G, Oliva F, et al.

Share

Articles

Efficacy and safety of inclisiran based on background lipid-lowering treatment

Landmesser U, Koenig W, Leiter LA, et al.

Share

Articles

Apolipoprotein C3 and cardiovascular risk: New insights from the ODYSSEY Outcomes trial

Catapano AL, Pirillo A, Tokgözoğlu L

Share

Articles

Implementation strategies for improving the care of familial hypercholesterolaemia from the International Atherosclerosis Society: next steps in implementation science and practice

Sarkies MN, Watts GF, Gidding SS, et al.

Share

Articles

Relation of Low-Density Lipoprotein Cholesterol, High-Sensitivity C-Reactive Protein, and Lipoprotein(a) Each to Future Cardiovascular Events and Death After Acute Coronary Syndrome on High-Intensity Statin Therapy: An Analysis of the Placebo Arm of ODYSSEY OUTCOMES

Steg PG, Szarek M, Jukema JW, et al.

Share

Articles

Effects of Evolocumab on Coronary Plaque Composition and Microcalcification Activity by Coronary PET and CT Angiography

Han D, Tzolos E, Park R, et al.

Share

Articles

Low-density lipoprotein cholesterol, C-reactive protein, and lipoprotein(a) universal one-time screening in primary prevention: the EPIC-Norfolk study

Kraaijenhof JM, Nurmohamed NS, Nordestgaard AT, et al.

Share

Articles

An Oral PCSK9 Inhibitor for Treatment of Hypercholesterolemia: The PURSUIT Randomized Trial

Koren MJ, Vega RB, Agrawal N, et al.

Share

Articles

Durability and efficacy of solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3, in adults with mixed dyslipidaemia (PROLONG-ANG3): a double-blind, randomised, placebo-controlled, phase 2 trial

Ray KK, Oru E, Rosenson RS, et al.

Share

Articles

Effect of ANGPTL3 Inhibition With Solbinsiran in Preclinical and Early Human Studies

Ray KK, Linnebjerg H, Michael LF, et al.

Share